Related Experiment Videos

CDK inhibition and cancer therapy

M D Garrett1, A Fattaey

  • 1Onyx Pharmaceuticals, 3031 Research Drive, Richmond, California 94806, USA. mgarrett@onyx-pharm.com

Insights

The cell-division cycle relies on cyclin/CDK complexes for control. Genetic alterations in these complexes are linked to cancer, driving the development of targeted CDK inhibitors for drug discovery.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The cell-division cycle is a fundamental biological process.
  • Regulation involves cyclin-dependent kinases (CDKs) and their partners.
  • Precise cell cycle control is crucial for preventing errors in DNA replication and cell division.

Purpose of the Study:

  • To highlight the critical role of cyclin/CDK complexes in cell cycle regulation.
  • To underscore the significance of CDKs, their regulators, and substrates as targets in human cancers.
  • To emphasize the ongoing efforts in drug discovery targeting CDKs.

Main Methods:

  • Review of evidence linking cell cycle regulators to cancer genetics.
  • Analysis of drug discovery approaches targeting CDK pathways.

Main Results:

  • Strong evidence implicates CDKs, regulators, and substrates in genetic alterations across numerous human cancers.
  • Numerous small molecule inhibitors targeting CDKs have been identified.

Conclusions:

  • Dysregulation of the cell-division cycle through genetic alterations in CDKs is a hallmark of many cancers.
  • CDK inhibitors represent a promising therapeutic strategy for cancer treatment.

Related Concept Videos